Treatment of Recurrent High Grade Glioma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Neuro-Oncology".
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 422
Special Issue Editor
Special Issue Information
Dear Colleagues,
Given the pathology of high-grade gliomas, it is understood that they are incurable and will recur at some point through the evolvement of the disease. The approach to treatment is multifactorial and there are many components influencing decisions regarding the most effective and ethical course for best care practices.
This Special Issue aims to explore all areas of treatment including:
- Surveillance imaging and diagnostic work up to ensure accurate and timely identification of recurrence.
- The role of surgery in first time and subsequent recurrences with the use of awake surgery and 5-ALA fluorescence-guided surgery for maximal safe resection of recurrent high-grade gliomas
- The use of stereotactic radiosurgery as adjunct treatment to previously radiated tumours with the nuances of effective targeted treatment.
- Current systemic treatment options with chemotherapy and immunotherapy to provide knowledge of innovative techniques in evolving therapies.
- The role of physiological testing and rehabilitation to optimize recovery and quality of life in patients living with the diagnosis of high-grade glioma.
Dr. John Sinclair
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- high-grade glioma
- glioblastoma
- astrocytoma
- oligodendroglioma
- recurrence
- awake craniotomy
- 5-ALA fluorescence-guided surgery
- spectroscopy perfusion MRI
- stereotactic radiosurgery
- chemotherapy
- immunotherapy
- physiological rehabilitation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
